Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation (NCT05232032)
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.1. (Pharmacological Manipulation)
🩺 Plain-English Summary (8th-Grade Level)
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
Who can join: Review the eligibility criteria below.
Location: Mclean Hospital — Belmont, Massachusetts
Age range: 18 Years to 45 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Mclean Hospital — Belmont, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 855-4434
Email: ezhang24@mclean.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depressive Disorder, Major
- Psilocybin for Major Depressive Disorder (MDD) — Birmingham, Alabama
- A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder — Birmingham, Alabama
- Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Boston, Massachusetts
- bWell-D Pilot Randomized Controlled Trial — Vancouver, British Columbia
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — Birmingham, Alabama
Explore by condition: All Depressive Disorder, Major clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.